GSK1120212 in Surgically Resectable Oral Cavity Squamous Cell Cancer
Status:
Completed
Trial end date:
2015-12-01
Target enrollment:
Participant gender:
Summary
This phase II trial studies how trametinib effects tumor cells in patients with oral cavity
squamous cell carcinoma that can be removed by surgery. Trametinib may shrink the tumor by
blocking an enzyme pathway needed for cell growth.